These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 20152505)

  • 1. Editorial comment.
    Slawin KM
    Urology; 2010 Feb; 75(2):444-5; author reply 445. PubMed ID: 20152505
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment.
    Moul JW
    Urology; 2010 Feb; 75(2):445-6; author reply 446. PubMed ID: 20152507
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial comment.
    Makarov DV
    J Urol; 2009 Nov; 182(5):2255-6. PubMed ID: 19758643
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial comment.
    Naselli A
    J Urol; 2009 Nov; 182(5):2256. PubMed ID: 19758664
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial comment.
    Nguyen PL
    J Urol; 2010 Mar; 183(3):989. PubMed ID: 20083273
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial comment.
    Porter MP
    J Urol; 2010 Mar; 183(3):982; discussion 983. PubMed ID: 20083274
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen.
    McDonald MW
    J Urol; 1998 Oct; 160(4):1442. PubMed ID: 9751386
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial comment.
    Carter HB
    Urology; 2009 Sep; 74(3):658; author reply 659. PubMed ID: 19716923
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial comment.
    Epstein JI
    J Urol; 2010 Mar; 183(3):1001. PubMed ID: 20089268
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial comment.
    Vollmer RT
    J Urol; 2010 Mar; 183(3):1001-2. PubMed ID: 20089267
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial comment on: prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy.
    Ciatto S
    Eur Urol; 2010 Apr; 57(4):630. PubMed ID: 19375847
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial comment on: prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy.
    Semjonow A
    Eur Urol; 2010 Apr; 57(4):629-30. PubMed ID: 19375846
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial comment on: systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy.
    Greene DR
    Eur Urol; 2007 Sep; 52(3):744-5. PubMed ID: 17350749
    [No Abstract]   [Full Text] [Related]  

  • 14. Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database.
    Chang SL; Freedland SJ; Terris MK; Aronson WJ; Kane CJ; Amling CL; Presti JC
    Urology; 2010 Feb; 75(2):439-44. PubMed ID: 19819536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial comment on: Oncological and functional results of antegrade radical retropubic prostatectomy for the treatment of clinically localised prostate cancer.
    van der Poel HG
    Eur Urol; 2008 Mar; 53(3):561-2. PubMed ID: 17683855
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial comment on: systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy.
    Trpkov K
    Eur Urol; 2007 Sep; 52(3):743-4. PubMed ID: 17350751
    [No Abstract]   [Full Text] [Related]  

  • 17. Can perineural invasion on prostate needle biopsy predict prostate specific antigen recurrence after radical prostatectomy?
    de la Taille A; Rubin MA; Bagiella E; Olsson CA; Buttyan R; Burchardt T; Knight C; O'Toole KM; Katz AE
    J Urol; 1999 Jul; 162(1):103-6. PubMed ID: 10379750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial comment on: Prostate-specific antigen improves the ability of clinical stage and biopsy gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
    Stenman UH
    Eur Urol; 2007 Oct; 52(4):1074-5. PubMed ID: 17383813
    [No Abstract]   [Full Text] [Related]  

  • 19. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
    Bañez LL; Sun L; Trock BJ; Han M; Partin AW; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Moul JW; Freedland SJ
    J Urol; 2009 Aug; 182(2):491-6; discussion 496-8. PubMed ID: 19524974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial comment on: Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
    van der Poel HG
    Eur Urol; 2009 May; 55(5):1133-4. PubMed ID: 18585847
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.